ABOUT US

TCR2 Therapeutics is an immuno-oncology company that has pioneered a novel class of T cell therapies for solid tumors that utilize the full signaling power of complete T cell receptors (TCR). TCR2 has developed a unique proprietary TRuCâ„¢ platform which can reprogram the natural TCR complex to elicit rapid killing of cancer cells with persistence and low cytokine release. The company has demonstrated superior activity against several tumor targets in preclinical models compared to CAR T cells and will advance its lead program TC-210 into the clinic in 2018.

TCR2 was founded in 2015 by Dr. Patrick Baeuerle and backed with a $44.5M Series A financing led by MPM Capital and F2 Ventures. It has since assembled a world-class team of immunotherapy experts and entrepreneurs located in the heart of Kendall Square in Cambridge, MA.


RECENT DEVELOPMENTS

February 5, 2018
TCR2 Therapeutics to Present at the 2018 Keystone Symposia Conference on Emerging Cellular Therapies: T Cells and Beyond

January 3, 2018
TCR2 Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

November 9, 2017
TCR2 Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

November 2, 2017
TCR2 Therapeutics Appoints Cell Therapy Pioneer Dr. Stephan Grupp to Advisory Board

October 31, 2017
TCR2 Therapeutics to Present New Data from its TRuC TM T Cell Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 11, 2017
TCR2 Therapeutics Appoints Leading Cell Therapy Expert as Chief Medical Officer

September 15, 2017
TCR2 Therapeutics Named One of the 15 Innovative Immuno-Oncology Biotechs to Watch in 2018 by Immuno-Oncology Frontiers

August 29, 2017
TCR2 Therapeutics to Present Solid Tumor Data at CAR-TCR Summit and CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

August 8, 2017
TCR2 Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

June 13, 2017
TCR2 Therapeutics Presents Positive Solid Tumor Data for its Novel TRuCâ„¢ Engineered T Cell Therapies at the World Preclinical Congress

May 16, 2017
TCR2 Therapeutics to Present at the 2017 UBS Global Healthcare Conference

February 28, 2017
TCR2 Therapeutics to Present at the Cowen and Company 37 th Annual Health Care Conference

December 7, 2016
TCR2 Therapeutics Launches from Stealth Mode to Accelerate Development of Novel Cancer Immunotherapies